Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

about

On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome.

P2860

Q38711705-CA2712B2-523A-452F-8AFC-EAE978495873

P2860

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

Item

http://www.wikidata.org/entity/Q58447452

description

im Oktober 2015 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 15 October 2015

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2015

@uk

name

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

@en

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

@nl

type

Item

label

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

@en

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

@nl

prefLabel

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

@en

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

@nl

P1476

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

@en

P2093

Bryan Dicken

http://www.w3.org/2001/XMLSchema#string

Dana Boctor

http://www.w3.org/2001/XMLSchema#string

David L Sigalet

http://www.w3.org/2001/XMLSchema#string

Elaine de Heuvel

http://www.w3.org/2001/XMLSchema#string

Mary Brindle

http://www.w3.org/2001/XMLSchema#string

Sonia Butterworth

http://www.w3.org/2001/XMLSchema#string

Vikram Karnik

http://www.w3.org/2001/XMLSchema#string

Viona Lam

http://www.w3.org/2001/XMLSchema#string

P2860

Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

Natural history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure Consortium.

Medical management of pediatric intestinal failure.

Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2.

Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.

Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome.

Elements of successful intestinal rehabilitation.

Plasma citrulline concentration reflects enterocyte mass in children with short bowel syndrome.

P304

844-852

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0148607115609566

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jens Juul Holst

Bolette Hartmann

Linda M Casey

P577

2015-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26471991

http://www.w3.org/2001/XMLSchema#string

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

about

P2860

P2860

Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698